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Abstract
Objective: The aim of this study was to evaluate the 
definition of Procedure-related mortality after endovascular 
aneurysm repair (EVAR) as defined by the Committee for 
Standardized Reporting Practices in Vascular Surgery.
Methods: Data on patients with an AAA were taken from 
the EUROSTAR database. The patients underwent EVAR 
between June 1996 and February 2004 and were analyzed 
retrospectively. Explicit probability of cause of death was 
recorded. The time interval from operation, hospital 
discharge or second interventions till death was recorded.
Results: A total of 589 out of 5612 patients (10.5%) died 
after EVAR in total follow up and all causes of death were 
included. 141 (2.5%) patients died due to aneurysms reported 
after the EVAR procedure of which 28 (4.8%) were ruptures,
25 (4.2%) graft-infections and 88 (14.9%) patients who died
within 30 days after the initial procedure (present definition, 
also known as short term clinical outcome). In addition 25 
patients died after 30 days, but were then (at moment of 
death) still in the hospital, or were transferred to a nursing 
home for further re-evaluation, or needed second  
interventions. Taking into account the duration of  
hospitalization and mortality immediately after procedure- 
related second interventions, 49 delayed deaths might also 
be regarded as being EVAR procedure-related.
Conclusion: Delayed deaths are a considerable proportion 
of procedure-related deaths after EVAR within the revised 
time frame.
Descriptors: Aortic aneurysm, abdominal, mortality. Aortic 
aneurysm, abdominal, surgery. Stents. Blood vessel prosthesis 
implantation, mortality.
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Resumo
Objetivo: O objetivo do estudo foi avaliar a definiçào da 
mortalidade relacionada ao procedimento após tratamento 
endovascular do aneurisma de aorta abdominal (EVAR) como 
definido pelo Committee for Standardized Reporting Practices 
in Vascular Surgery.
Método: Dados de pacientes com aneurisma de aorta 
abdominal foram analisados do banco de dados EUROSTAR. 
Os pacientes foram submetidos ao EVAR entre junho de 1996 
a fevereiro de 2004 e foram estudados retrospectivamente. A 
probabilidade explicita da causa de morte foi registrada. O 
intervalo entre a operaçào, alta hospitalar ou intervençào 
secundaria até a morte foi registrado.
Resultados: De um total de 5612 pacientes, 589 (10,5%) 
faleceram após o EVAR em acompanhamento total e qualquer 
causa de morte foi inclusa. Cento e quarenta e um pacientes 
(12,5%) morreram devido a causa relacionada ao aneurisma, 
sendo que 28 (4,8%) foram rupturas, 25 (4,2%) infecçoes do
implante e 88 (14,9%) foram pacientes que morreram num 
prazo de 30 dias após o procedimento inicial (definiçào 
atualmente utilizada, também conhecido como resultado 
clínico a curto prazo). Além disso, 25 pacientes faleceram 
após 30 dias, mas continuavam ainda hospitalizados (ou 
transferidos a home-care para reavaliaçào posterior, ou 
necessitaram intervençào secundaria). Levando em conta a 
duraçào da admissào ao hospital e a mortalidade imediata 
após o procedimento relacionada a intervençoes secundarias,
49 mortes tardias também podem ser relacionadas ao EVAR.
Conclusao: M orte tardia com poe uma proporçào  
consideravel da mortalidade relacionada ao EVAR dentro do 
tempo de analise revisado.
Descritores: Aneurisma da aorta abdominal, mortalidade. 
Aneurisma da aorta abdominal, cirurgia. Contenedores. 
Implante de prótese vascular, mortalidade.
INTRODUCTION
Minimal invasive surgery is frequently used nowadays 
to treat abdominal aortic aneurysms (AAA) because of the 
many benefits this therapy procures [1-3]. The motivation for 
aneurysm treatment is to eliminate the risk of rupture and 
death [4,5]. Therefore, by definition, the primary outcome 
criteria for endovascular aneurysm repair (EVAR) include the 
prevention of aneurysm rupture; death from aneurysm rupture 
and procedure-related death that may result from primary 
treatment [4]. According to the Committee for Standardized 
Reporting Practices in Vascular Surgery the present definition 
of procedure-related death is mortality that occurs within a 
period of 30 days after the initial procedure, due to rupture, 
graft infection and mortality related to second interventions
[4]. Standardized reporting of deaths and complications is 
necessary to establish endograft exclusion as safe and 
effective therapy for AAA-treatment. These standards are 
necessary to compare endovascular procedures with other 
minimally invasive techniques and conventional surgery for 
patients at low or high risk [6].
Several studies reported that 10.5% of the patients that 
underwent EVAR died due to any reason [2,5,7-9], probably 
due to the high age of the patients and co-morbidity that 
was pre-existent before EVAR. The current definition of 
procedure-related mortality according to the Reporting 
Standards has not been evaluated so far. It is not always 
obvious whether or not the reason of mortality is EVAR-
related. Consequently an arbitrary time frame of 30 days 
after the initial procedure is used nowadays [4]. Our analyses 
have shown that after the thirty-day time frame, 
complications still become obvious and lead to mortality. 
Therefore, the aim of this study was to assess the 
proportions of deaths in each category that fall within the 
current definition of EVAR Procedure-related death.
METHODS
The EUROSTAR (European Collaborators on Stent-graft 
Techniques for Abdominal Aortic Aneurysm Repair) project 
was launched in 1996 with the objective of collecting data on 
the endovascular treatment of aneurysms [10]. Patient 
enrolment was between June 1996 and February 2004. Excluded 
were patients with withdrawn devices (Stentor, Vanguard, 
first generation EVT, patients with AAA < 4 cm in diameter). 
Preoperative evaluation, operative details and follow-up data 
were collected. Follow-up protocol requires patient 
assessment by contrast-enhanced CT scan at 1, 3, 6, 12, 18 
and 24 months after the operation and annually thereafter. 
Surveillance protocol includes clinical examination and an 
annual plain abdominal X-ray. This information is stored on 
an “Oracle-based” database (Oracle Corporation, CA, USA.) 
for periodic analysis (website data entry programming was 
provided by KIKA medical services, Nancy, France). The 
registry has no core laboratory or external audit of source 
data (patient’s records and CT scans).
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Reminders for overdue follow-up data are regularly sent 
to the surgeons in the centers who participate in this project. 
The present cohort consisted of 5612 patients who 
underwent EVAR between June 1996 and February 2004. 
From different European countries, there were 153 centers 
involved in patient treatment and data procurement. 
Although CT scanning was the standard examination during 
follow-up, patients had either m agnetic resonance 
angiography or duplex scanning in 6% of the follow-up 
visits. Data was collected retrospectively and analyzed as 
well as scored by death cause. The cause of death of patients 
who underwent a second intervention (SI) to treat the 
aneurysm was scored after their last procedure. The 
characteristics of the patients who died after EVAR were 
analyzed. They were analyzed for the presence of possible 
precipitating factors.
Variables
The study variables included the clinical characteristics 
of patients such as ASA-class, diabetes, smoking, 
hypertension, cardiac and pulmonary co-morbidities. The 
procedure data included the type of stent graft used and 
the occurrence of peri-operative complications, as reported 
by the surgeon. Complications included the occurrence of 
endoleaks, vascular occlusions or intra-operative death. 
Other complications that were assessed were myocardial 
infarction, stroke, graft-infection, AAA-rupture and 
procedure- or device-related events including (early) 
conversion to a conventional procedure. Events, seen during 
follow-up, included endoleaks (type I-IV), endograft 
thrombosis, second interventions, rupture of the aneurysm 
and death of the patient.
The causes of death were divided into the following 
groups; AAA-rupture, graft infection, cancer, cardiovascular, 
renal, multiple organ failure, pulmonary and other and 
unknown. According to reporting standards the deaths were 
divided into procedure-related and non-procedure-related. 
Deaths within 30 days after EVAR were regarded as 
procedure-related, those occurring after 30 days as non­
procedure-related.
Analysis
Time between date of discharge and date of death was 
considered. First the Procedure-related death was analyzed 
according to the current Committee definition. If the number 
of days between operation and death was < 30 it was 
regarded as procedure-related  m ortality. Second 
interventions (SI) were not regarded. Graft infections and 
AAA-ruptures were always regarded as procedure-related 
events. Secondly, the patients with non-procedure-related 
deaths according to the Reporting Standards were studied 
further. If the time (in days) between hospital discharge and 
death or between SI and death did not exceed 30 days these
patients were also regarded as having a procedure-related 
death. Kaplan Meier curves were used to represent survival 
and freedom from procedure-related mortality. Because of 
the large number of small centers, we decided to categorize 
the centers as large (>30 cases), middle (10-30 cases) and 
small (<10 cases) to make statistical analysis possible. Of the 
153 centers, 41 had a team experience of more than 30 cases, 
44 operated 10 to 30 patients, and 66 performed less than 10 
operations. This distribution of team experience was similar 
in the patients who did not survive as in those who did.
RESULTS
The EUROSTAR database consisted of 5612 patients, 
93% was male; the mean age was 71 years (range: 53-100 
years) and the average aneurysm diameter was 55mm (range: 
33-145mm). Mean duration of the initial procedure was 137 
minutes (range: 25-785 min) with an average hospital stay of 
6 days (range: 0-163). Total follow up period of all patients 
who underwent EVAR was 8960 person-years. The 
completeness of the follow-up data is 77%. Baseline 
characteristics of the patients are shown in Table 1.









Diabetes Yes 78 (14.5)
No 461 (85.5)
Smoking Yes 298 (55.0)
No 244 (45.0)
Hypertension Yes 328 (60.5)
No 214 (39.5)
Cardiac problems Yes 368 (68.1)
No 172 (31.9)
Cardiac signs Yes 114 (21.5)
No 416 (78.5)
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Overall procedure-related mortality of the 5612 patients 
who underwent the EVAR procedure was 2.5% (141 patients) 
and 589 patients died due to any reason (10.5%). The 8-year 
survival of patients who underwent EVAR is 70%. Causes 
of death included rupture (4.8%), cancer (15.5%), 
cardiovascular problems (37.4%), pulmonary problems
Table 2. Procedure related mortality according to Reporting 
Standards definition and the definition including the 
period after discharge and SI
Mortality Number of 
patients*
AAA -  rupture
Graft infection 28 (4.8)
Mortality within 30 days 25 (4.2)
after procedure 88 (14.9)
Total of procedure related
deaths 141 (23.9)
Mortality within 30 days
after discharge 25 (4.2)
Mortality within 30 days
after SI 24 (4.1)
Total deaths according
definition including period 190 (32.3)
*Overall calculation o f  the 589patients who died
(7.7%), graft infections (4.2%), and other or unknown 
reasons (23.6%). The 589 patients who died after EVAR had 
a mean age of 74 years (range: 52-94 years). Their mean 
duration of the procedure was 164 minutes (range: 30-785 
min) and the mean hospital stay was 8.9 days (range: 0-163 
days). Patients who died after EVAR, often experienced co­
morbidity or showed precipitating risk factors.
The procedure-related mortality based on the Standard 
Reports definition was 16 per 1000 treated patients per year 
(1.6%). Overall, 141 out ofthe 589 deaths (24%) died because 
of the procedure. Eighty-eight patients (14.9%) died within 
30 days after the initial EVAR procedure (Table 2), 28 patients 
(4.8%) died due to AAA-rupture and 25 died due to graft- 
infection (4.2%). The majority of the patients died because 
of cardiovascular complications (29.8%) and multi-organ 
failure (MOF) (10.6%) (Table 3). The mean duration of the 
initial EVAR procedure of patients with procedure-related 
death was 206 minutes (range: 30-785 min). The mean age of 
these 141 patients was 76 years (range: 52-94 years).
A total of 83 patients had a prolonged hospital stay of 
more than 30 days after primary intervention. Of these 83 
patients, 25 patients (4.2%) died within 30 days after hospital 
discharge. The mean duration of hospital admission of these 
25 patients was 47 days (range: 0-163 days). Furthermore, 
669 (17%) of the 3928 patients still under follow up were 
submitted to a SI after hospital discharge. A total of 32 
patients died after SI, of which 24 (3.6%) died within 30 days 
(Table 4).
Table 3. Comparision: procedure related deaths according to the Reporting Standards definition vs. the definition 
including the period of discharge and SI
Reporting Standards definition Definition including period
Procedure Non-procedure Procedure Non-procedure
related related related related
Cause of death mortality mortality mortality mortality
(N=589) n° (%) n° (%) n° (%) n° (%)
Overall 141 (23.9) 448 (76.1) 190 (32.2) 399 (67.7)
Cancer 1 (0.7) 117 (26.1) 13 (6.8) 94 (23.6)
Cardiovascular 42 (29.8) 159 (35.5) 76 (35.3) 149 (37.3)
Graft-infection 25 (17.7) 0 (0.0) 25 (13.2) 0 (0.0)
MOF 15 (10.6) 8(1.8) 16 (8.4) 0 (0.0)
Pulmonary 11 (7.8) 38 (8.5) 17(8.9) 32 (8.0)
Renal 3 (2.1) 9 (2.0) 11 (5.8) 1 (0.3)
AAA-rupture 28 (19.9) 0 (0.0) 28 (14.7) 0 (0.0)
Unknown 7 (5.0) 63 (14.1) 2 (1.1) 66 (16.5)
Others 9 (6.4) 54 (12.1) 11 (5.8) 57 (14.3)
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0 5612 107 0,981
1 5505 110 0,980
3 4830 148 0,972
6 4575 277 0,943
12 4175 347 0,923
18 3262 392 0,907
24 2527 453 0,881
36 2064 519 0,839
48 1317 561 0,792
60 703 580 0,749
72 331 586 0,718
84 139 588 0,694
96 57 589 0,694
Ten SIs were transfemoral procedures. 10 patients 
underwent a conversion of which five were because of 
AAA-rupture, one because of stent-graft migration and four 
because of unknown reasons. Finally, four patients 
underwent an extra-anatomical intervention. If mortality 
because of SI and the mortality in the 30-day period after 
hospital discharge are taken into account, 49 more deaths 
should be regarded as procedure-related. These additional 
49 patients died mainly (42%) due to cardiovascular 
complications such as myocardial infarction, emboli and 
strokes. The overall procedure-related mortality after EVAR 
showed an increase from 16 to 24 per 1000 treated patients 
per year in this study.
DISCUSSION
Endovascular aneurysm repair (EVAR) is, besides the 
conventional procedure and “watchful-waiting” strategy, a 
relatively new manner to manage AAA-patients [3,11]. 
Recently the Committee for Standardized Reporting Practices 
in Vascular Surgery published definitions of outcome 
measures in endovascular surgery. This study was designed 
to evaluate the current definition of procedure-related 
mortality of patients after EVAR, one of the most important 
outcome measures for treatment evaluation available. 
Although the overall mortality after EVAR is low (7-10%) 
the results from our study showed a considerable additional
number of delayed deaths that seemed to be procedure- 
related [11-13]. According to the Standard Reports definition 
2.5% of the patients died because of the procedure. However 
the Standard Reports definition does not consider mortality 
within a time frame of 30 days after SIs or after hospital 
discharge. Taking into account mortality in the 30-day period 
immediately after hospital discharge and after SI, an 
additional 49 patients’ deaths were procedure-related.
Again, the importance of using hard clinical outcomes is 
necessary to evaluate EVAR in AAA patients [14]. Risk 
factors such as co-morbidity and medication are becoming 
more important. The recent published conclusion of the 
DREAM Trial informed our colleagues that “the initial 
survival advantage over open aneurysm repair, however, is 
not sustained after the first postoperative year” [18]. The 
mortality rate of 2.5% in the present study population is 
comparable to those of the EVAR-1 and the DREAM trials. 
In these studies mortality rates of 2.7% and 3% were recorded 
for elective EVAR [ 18,20].
The main cause of late postoperative death in both trials 
was cardiovascular, confirming the impact of co-morbidity 
in EVAR patients. The E VAR-2 study was conducted in 
patients unfit for open aneurysm repair. It showed that EVAR 
is not a safe procedure in such high-risk patients [19]. It 
also raised concern about the medical treatment of these 
patients, fuelling the attention for co-morbidity and 
pharmacological interventions.
Risks on developing complications after EVAR are high, 
supporting the cautious use of EVAR [14]. Both patient 
characteristics and procedural variables are independent 
risk factors for complications and mortality.
According to the current definition of The Reporting 
Standards 141 patients deaths were related to the procedure. 
Taking into account the time between delayed discharge 
and death and the time after SI and death, an additional 49 
patients should be regarded as having aneurysm-related 
deaths. Other studies, such as the ones by Chaikof et al. 
(2002) and Dias et al. (2002) reported lower aneurysm-related 
mortality percentages (respectively 6.5% and 2.6%) [6,9]. 
The incidence of procedure related mortality after EVAR 
(2.5%) in the EUROSTAR-cohort is comparable with the 
previously reported institutional series.
The EUROSTAR population has a thorough follow up 
protocol. It requires contrast-enhanced CT scans at 1, 3, 6, 
12, 18 and 24 post-operative months and annually thereafter. 
The possible development of a new or persisting endoleak 
can be noticed.
While endovascular AAA repair has several advantages 
over open surgical repair in the short-term, there is still 
concern regarding its durability [15]. The advantages of 
EVAR are reasonably exciting. In fact there is no need for a 
laparatomy and the anesthesia period can be much shorter
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and lighter. Therefore endovascular surgery is a good option 
for patients with poor medical conditions (ASA-class 3 or 
4) and therefore unfit for open procedures [2]. This group of 
patients typically demonstrates a high prevalence of co­
morbidity, such as peripheral arteriosclerosis, coronary heart 
diseases, (renal-vascular) hypertension, diabetes mellitus 
or other medical disorders [13,16]. Procedure-related 
mortality in patients unfit for a conventional procedure is 
higher than in those with good conditions [10]. Considering 
the outcomes of this study and in particular the causes of 
mortality, EVAR may cause an increased risk of procedure- 
related complications and death for patients suffering from 
disorders such as cancer, cardiovascular problems or 
pulmonary disease.
It has been demonstrated that implantation of a foreign 
body in the circulation may cause a systemic response such 
as inflammation and platelet activation [9,12]. Inflammation 
and platelet activation may cause additional complications, 
such as graft-infection, thrombosis and embolic processes 
in lungs, brain or gastric-intestinal system [2,17]. These 
complications can be lethal and will not always be identified 
as procedure-related mortality for patients who underwent 
EVAR because of the very fact that these complications can 
occur in the short-term as well as in the long term [4]. The 
complications caused by EVAR are procedure-related by 
definition. The definition of the Committee on Reporting 
Standards specifies that a patient, who died after 30 
postoperative days, is non-procedure-related. The thirty- 
day postoperative timeframe was also arbitrarily chosen in 
our study but several patients stayed in the hospital for 
longer than 30 days. These were included in the definition 
of procedure-related death. Variations in the severity of 
complications and the effect of SI remain uncertain factors 
for measuring hard clinical outcomes.
In our study few patients died immediately after SI. The 
type of SI was not of significance. Because of the fact that 
several patients will need SI after EVAR, mortality and 
morbidity will be of significance.
In this study, 12% of the study population underwent 
SI, 4.1% of these patients died within thirty days after this 
SI. These results are comparable with other studies such as 
Zarins et al. (2000). They concluded that 15 late deaths (10%) 
occurred after SI [3]. An analysis of the causes of death of 
patients who underwent SI showed that more than 20% of 
the patients who underwent a SI for rupture died within 30 
postoperative days.
CONCLUSION
In conclusion, delayed deaths make up for a considerable 
proportion of procedure-related mortality after EVAR within 
this revised time frame.
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Endovascular aortic aneurysm repair (EVAR) is a recent 
procedure that is less invasive compared to conventional 
surgery. A comparison with the conventional procedure is
fundamental and should be achieved in two ways: with 
clinical trials and with registers. Two clinical trials (EVAR 1 
and DREAM) demonstrated lower mortality rates using the 
endovascular procedure when compared to conventional 
surgery in the first 30 days after treatment for abdominal 
aortic aneurysms (AAA).
In the medium-term analysis of these studies (1 to 4 
years) there was a loss of the initial benefit over time with a 
tendency of evening out, mainly in respect to higher mortality 
rates in the EVAR Group, with this being considered ‘not 
related’ to the procedure.
Initiated in 1996, EUROSTAR (European Collaborators 
on Stent-graft Techniques for Abdominal Aortic Aneurysm 
Repair), the main register accompanying the used of 
endoprostheses for AAAs, includes a large number of 
patients (more than 5000) and has a rigid follow-up protocol 
and is therefore closer to the real life scenario than clinical 
trials.
The Koning et al. study in this edition of the journal 
raises an important aspect in the evaluation of results after 
the endovascular repair of abdominal aortic aneurysms. The 
definition of procedure-related mortality rate should be more 
comprehensive than that restricted to 30 days following the 
procedure. The additional late deaths identified by the 
authors as being related to the aneurysm and/or procedure 
in the EUROSTAR register only reinforce the importance of 
the necessity of careful follow-ups of patients using imaging 
methods with the aim of identifying and treating potential 
complications and to identify late deaths related to the 
aneurysm. Long-term results are necessary for the true role 
of this procedure to be established.
*President o f  Professional Defence Committee o f  
Brazilian Society o f  Cardiovascular Surgery
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The possibility of endovascular treatment of abdominal 
aorta aneurysms (AAAs) has occupied a significant place 
in present-day cardiovascular scenery. Aggregating the 
theoretical advantages of the less invasive nature of the 
technique with the reduced risks in comparison to the 
conventional approach, endovascular aneurysm repair 
(EVAR) has been proposed not only as an alternative for 
high operative risk patients, but as a potential substitute to 
open chest surgery.
Recently, analysis of the EVAR-1 studies demonstrated 
that, even though there is a reduction of around 2/3 of early 
deaths in the endovascular arm of the trial, this benefit is
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not sustained over a 4-year follow-up period, due to the 
high com plication rates and late re-interventions. 
Additionally, the DREAM trial demonstrated that the 
equivalent survival curve at 2 years was justified for the 
EVAR group, only because of the “advantage” obtained in 
the in-hospital period.
In this edition of the BJCVS, Koning et al. bring a new 
and interesting ingredient into the discussion, EVAR versus 
conventional surgery: the importance of redefining the 
notion of death related to the procedure based on data from 
the real world. Supported by the data in the EUROSTAR 
register, the authors propose that late mortality related to 
EVAR can be significantly higher than that initially 
recognized if data of subsequent interventions are taken
into account. Other data, brought to our attention, are in 
respect to the high late cardiovascular mortality rate even in 
a group under such rigorous clinical control, reinforcing the 
necessity of aggressive treatment of atherosclerosis, 
independent of the technique used for AAA repair.
Finally, the Koning et al. study contributed greatly to 
the real world; if on one hand it does not have the evidence 
level of clinical trials, on the other it is closer to the day-to- 
day practice and contributes to clinical judgment.
• PhD in Cardiology by Federal University o f  Rio 
Grande do Sul. Cardiovascular surgeon o f  Sao Lucas 
Hospital o f  PUCRS. Associate editor o f  BJCVS.
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